Boxer Capital, LLC Bei Gene, Ltd. Transaction History

Boxer Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $65.7 Million - $103 Million	-264,188 Reduced 34.57%	500,000 $135 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $91.2 Million - $134 Million	-350,000 Reduced 31.41%	764,188 $266 Million
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $35.8 Million - $54.2 Million	189,188 Added 20.45%	1,114,188 $319 Million
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $3.02 Million - $3.71 Million	25,000 Added 2.78%	925,000 $113 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $28.9 Million - $47.3 Million	270,000 Added 42.86%	900,000 $126 Million
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $2.92 Million - $5.32 Million	30,000 Added 5.0%	630,000 $106 Million
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $39.7 Million - $62.1 Million	600,000	600,000 $62.1 Million

254

42.4M

135K

111K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Boxer Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Boxer Capital, LLC with notifications on news.